Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05295589
Title Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

peritoneum cancer

fallopian tube cancer

ovarian serous carcinoma

ovarian endometrial cancer

ovarian cancer

Therapies

Topotecan

Pegylated liposomal-doxorubicin

Copanlisib + Olaparib

Paclitaxel

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.